A SARS-CoV-2-specific CAR-T-cell model identifies felodipine,fasudil,imatinib,and caspofungin as potential treatments for lethal COVID-19

扫码查看

原文链接

万方数据

外文摘要：Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)-induced cytokine storm is closely associated with coronavirus disease 2019(COVID-19)severity and lethality.However,drugs that are effective against inflammation to treat lethal COVID-19 are still urgently needed.Here,we constructed a SARS-CoV-2 spike protein-specific CAR,and human T cells infected with this CAR(SARS-CoV-2-S CAR-T)and stimulated with spike protein mimicked the T-cell responses seen in COVID-19 patients,causing cytokine storm and displaying a distinct memory,exhausted,and regulatory T-cell phenotype.THP1 remarkably augmented cytokine release in SARS-CoV-2-S CAR-T cells when they were in coculture.Based on this"two-cell"(CAR-T and THP1 cells)model,we screened an FDA-approved drug library and found that felodipine,fasudil,imatinib,and caspofungin were effective in suppressing the release of cytokines,which was likely due to their ability to suppress the NF-κB pathway in vitro.Felodipine,fasudil,imatinib,and caspofungin were further demonstrated,although to different extents,to attenuate lethal inflammation,ameliorate severe pneumonia,and prevent mortality in a SARS-CoV-2-infected Syrian hamster model,which were also linked to their suppressive role in inflammation.In summary,we established a SARS-CoV-2-specific CAR-T-cell model that can be utilized as a tool for anti-inflammatory drug screening in a fast and high-throughput manner.The drugs identified herein have great potential for early treatment to prevent COVID-19 patients from cytokine storm-induced lethality in the clinic because they are safe,inexpensive,and easily accessible for immediate use in most countries.

外文关键词：

COVID-19SARS-CoV-2CAR-Tanti-inflammationNF-κB pathway

作者：

Lin Xia、Lun-zhi Yuan、Ya-hong Hu、Jun-yi Liu、Guo-sheng Hu、Ruo-yao Qi、Tian-ying Zhang、Hua-long Xiong、Zao-zao Zheng、Hong-wei Lin、Jia-mo Zhang、Chao Yu、Ming Zhou、Jian Ma、Tong Cheng、Ri-rong Chen、Yi Guan、Ning-shao Xia、Wen Liu

展开 >

作者单位：

State Key Laboratory of Cellular Stress Biology,School of Pharmaceutical Sciences,Xiamen University,Xiang'an South Road,Xiamen,Fujian 361102,China

Fujian Provincial Key Laboratory of Innovative Drug Target Research,School of Pharmaceutical Sciences,Xiamen University,Xiang'an South Road,Xiamen,Fujian 361102,China

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Life Sciences,School of Public Heal

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Life Sciences,School of Public Health,Xiamen University,Xiang'an South Road,Xiamen,Fujian 361102,China

State Key Laboratory of Emerging Infectious Diseases,School of Public Health,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong SAR,China

展开 >

基金：

Fundamental Research Funds for the Central UniversitiesMinistry of Science and Technology of ChinaMinistry of Science and Technology of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNatural Science Foundation of Fujian Province of ChinaFundamental Research Funds for the Central UniversityFundamental Research Funds for the Central UniversityChina Postdoctoral Science Foundation

项目编号：

207202001042020YFA01123002020YFA080360082125028U22A20320919531143187131981761128015818611303702020J0200420720190145207202200032022M720119

出版年：

2023

DOI：

10.1038/s41423-023-00985-3

中国免疫学杂志(英文版)

中国免疫学会

中国免疫学杂志(英文版)

CSTPCDCSCDSCI

影响因子：0.731

ISSN：1672-7681

年,卷(期)：2023.20(4)

参考文献量83